Alphaform AG / Key word(s): Preliminary Results
21.02.2011 11:20
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
AD HOC PUBLICATION pursuant to § 15 of the WpHG (German Securities Trading
Act)
Preliminary Figures Financial Year 2010:
Strategic Repositioning Brings Results
The 2010 fourth quarter with another upswing
2010 consolidated net income increased from EUR-3.8 million EUR-1.5
million
For 2011, the company is anticipating a positive result
Feldkirchen, 21 February 2011 - Alphaform AG, a specialist in additive
manufacturing and a leading company in the area of orthopaedic implants and
instruments, on the basis of preliminary figures increased consolidated
revenues in the fourth quarter to EUR5.4 million, a year-on-year increase
of 13.5% against the previous-year figure of EUR4.8 million. The
improvement in the general economic situation generated a rise in incoming
orders especially in the Prototyping & Additive Manufacturing business
area. And the second business area, Medical Technology, also demonstrated a
clear upswing. EBITDA improved in the fourth quarter from EUR-1.1 million
to EUR+0.25 million. Consolidated net income for the fourth quarter
improved from EUR-1.5 million to EUR-0.2 million (up 83.8%). Consolidated
net income was impacted by write-downs from the acquisition of MediMet in
the amount of EUR-0.2 million (Q4 2009: EUR-0.2 million).
The preliminary figures for financial year 2010 show corporate revenues of
EUR20.3 million, which corresponds to an increase of 4.5 % compared to
2009. EBITDA increased by 144.2%, from EUR-1.4 million in 2009 to EUR0.63
million during the past financial year. Consolidated net income improved by
61.0 % from EUR3.8 million in 2009 to EUR-1.5 million in 2010. The
write-downs on the acquisition of MediMet of EUR1.9 million that
significantly impacted consolidated net income over the last two years will
be completed to the end of financial year 2010.
The strategic repositioning already introduced in the spring of 2008 by
expanding the Medical Engineering business was successful in 2010. This
business area benefited not only from the general recovery, but also from
synergies with the new Alphaform production site in Eschenlohe. The result
was revenues growth exceeding 20%. With Alphaform's new positioning, the
Medical Engineering business area accounts for about 40% of revenues and
has thus become a second pillar of the company. Alphaform anticipates that
this share will remain approximately stable over the next year.
In the traditional Alphaform area of prototyping, business returned
gradually over the course of the year, after having severely declined as a
result of the economic crisis. The German automobile manufacturers in the
premium segment that are important to Alphaform were more severely impacted
by the crisis and thus recovered particularly rapidly. In the fourth
quarter, incoming orders for prototyping received by Alphaform again
reached the 2008 level.
Outlook
Assuming a continued healthy economy, Alphaform expects a return to
profitability in 2011. The discontinuation of write-downs from the
acquisition of MediMet GmbH means an additional EUR0.84 million in the
result compared to 2010. If business remains at least stable, Alphaform
anticipates a positive result for the current financial year.
Contact:
Dr. Gordon Guth
CFO
ALPHAFORM AG
KapellenstraÃe 10
85622 Feldkirchen
Tel.: +49 89 905002 83
Fax: +49 89 9050021083
e-mail: gguth@alphaform.de
Internet: www.alphaform.de
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About Alphaform
Alphaform AG, headquartered in Feldkirchen near Munich, is a contract
manufacturer for complex components and products produced in smaller
batches, founded in 1996. The company is one of the European market leaders
in rapid manufacturing and rapid prototyping. The company has a leading
position throughout Europe in the manufacture of orthopaedic implants and
instruments. The Alphaform share is traded on the Frankfurt Stock Exchange
(FSE) under the abbreviation ATF and is listed in the Prime Standard
segment.
The core competence of Alphaform lies in the provision of comprehensive
application expertise with regard to processes and materials for the rapid
production of complex prototypes, tools, single components and small series
of plastics and metals. The focus of the company's work lies in orthopaedic
and medical technology, automotive, as well as aviation and aerospace.
There are Alphaform subsidiaries in Germany, Finland, Sweden and the UK.
About rapid manufacturing
Rapid manufacturing is automatic shift manufacturing of plastic and metal
parts, directly from CAD files and without casting moulds or press moulds.
Also known as direct manufacturing, 3D printing or e-manufacturing, rapid
manufacturing is seen globally as a growth field. For some years, these
manufacturing methods have enabled rapid tooling and rapid prototyping.
Because plant builders are continually developing new manufacturing methods
and machinery, as well as new materials, tool-free production will enable
more cost effective batch manufacturing and more customised products in
future. Many very sophisticated metal and plastic parts are only possible
thanks to the new manufacturing options that rapid manufacturing offers.
Rapid manufacturing is deployed above all in medical technology, aerospace
and the automotive industry.
21.02.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Alphaform AG
KapellenstraÃe 10
85622 Feldkirchen
Deutschland
Phone: +49 (0)89 905002 - 0
Fax: +49 (0)89 905002 - 90
E-mail: ir@alphaform.de
Internet: www.alphaform.de
ISIN: DE0005487953
WKN: 548795
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Alphaform AG: Preliminary Figures Financial Year 2010: Strategic Repositioning Brings Results
| Source: EQS Group AG